The patients included in this study were consecutive incident cases who had HER2-amplified locally advanced breast cancer and had received six cycles of docetaxel and carboplatin (TCb) NAC with trastuzumab and pertuzumab. This evidence concerns the gene ERBB2 and breast cancer.